NGS Panel - Solid Tumor - LUNG: BRAF-EGFR-HER2-KRAS-MET-PIK3CA

Back to the list
Eurofins Biomnis code

POUM1

Synonyms
  • Companion test
  • NGS
  • oncology
  • Solid tumor
  • Targeted therapy
Specialty

Genetics

Clinical significance

The NGS "LUNG1" panel associated with the FISH unitary test fulfil the routine needs of clinicians for prescribing targeted therapies for locally advanced or metastatic NSCLC. In 2020, the EGFR (mutation), ALK (rearrangement), ROS1 (rearrangement), RET (rearrangement),BRAF (mutation), NTRK (rearrangement) and MET (mutation) status can be used to guide the selection of targeted therapy (TMA (temporary marketing authorization)). In addition, KRAS status is included in this panel.

Preanalytics
  • Tumoral block included in paraffin or slides (6 slides 5µm) or DNA extract or Shavings (6 shavings of 5 µm)
  •   Ambient temperature
  • A tube specifically for this analysis : No
Further information

Use the specific request form B9-INTGB: Oncology-Solid tumors
The use of the S25UK transport bag is Mandatory.
Attach the anatomopathological report

Specific equipment available
  • S25 : Envelope Genetics and Molecular Oncology
Documents to download
Methodology

Search for variants on a targeted gene panel using high-throughput sequencing. Library preparation: Library Preparation Enzymatic Fragmentation Kit 2.0 Twist with UMI Capture-based enrichment (custom panel) Sequencing: NovaSeq Illumina (2x150bp) Bioinformatic analysis: Demultiplexing with BCLconvert / SeqOne SomaVar v2.7 RUO Theoretical detection threshold: 5% Minimum depth: 99% coverage at 200X (after UMI analysis) for Level I and II genes relevant to the indication, according to the 2024 ESMO recommendations (PMID: 38834388). >95% coverage at 200X for all other genes. Genome version: GRCh38

Turnaround time

15 days

Testing Laboratory

Biomnis Lyon

Contact(s)
Customer Care